Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Names Markison Acting CEO; President Macione Steps Down

This article was originally published in The Pink Sheet Daily

Executive Summary

Chief Operating Officer Brian Markison will assume the duties of CEO Jefferson Gregory and President Kyle Macione, who are both leaving the company. King taps former pharma industry exec Ted Wood as chairman.
Advertisement

Related Content

Mylan Fights For King; Plans Include Retention Bonuses For Employees
Mylan Fights For King; Plans Include Retention Bonuses For Employees
Mylan Wants King CFO To Oversee Tennessee Operations
Mylan Wants King CFO To Oversee Tennessee Operations
King Names Markison President & CEO
King Moves Sales & Marketing To N.J.; Andrzejewski Will Head Commercial Operations
King Intensifying CEO Search; Gregory To Immediately Step Down
King Intensifying CEO Search; Gregory To Immediately Step Down
CEO Gregory To Step Down, Search For Successor Underway
King Pharma Names Markison COO

Topics

Advertisement
UsernamePublicRestriction

Register

PS059442

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel